Enanta Pharmaceuticals | ENTA - Interest Expense On Debt


Enanta Pharmaceuticals reported $1.96M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Amgen USD 653M 94.99B Sep/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
AstraZeneca USD 371M 31M Sep/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 403M 4M Sep/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Halozyme Therapeutics USD 6.04M 457K Sep/2026
Heron Therapeutics USD 600K 100K Dec/2024
Immunic 197K 222K Dec/2025
Incyte USD 605K 23K Sep/2026
Insmed USD 20.41M 1.57M Sep/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 525M 46M Jun/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novartis USD 468M 6M Sep/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026